Clinical Trials
363
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (314 trials with phase data)• Click on a phase to view related trials
The Possible Range of No.4sb Lymph Node Dissection of Locally Advanced Distal Gastric Cancer
- Conditions
- Gastric Cancer (GC)No.4sb
- First Posted Date
- 2025-09-19
- Last Posted Date
- 2025-09-19
- Target Recruit Count
- 400
- Registration Number
- NCT07183150
- Locations
- 🇨🇳
Tianjin Medical University Cancer Hospital, Tianjin, Tianjin Municipality, China
Analysis of Deoxyribonucleic Acid and Ribonucleic Acid Next-Generation Sequencing in Non-Small Cell Lung Cancer Patients Without Pathological Complete Response Following Neoadjuvant Immunotherapy
- Conditions
- NSCLC
- First Posted Date
- 2025-09-17
- Last Posted Date
- 2025-09-17
- Target Recruit Count
- 300
- Registration Number
- NCT07179445
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital(Lead Center), Tianjin, China
Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer
- Conditions
- Extensive Stage Lung Small Cell Cancer
- Interventions
- Biological: DLL3 CAR-NK cellsDrug: Tislelizumab/Atezolizumab/ Durvalumab/Benmelstobart/Toripalimab/Serplulimab
- First Posted Date
- 2025-09-15
- Last Posted Date
- 2025-09-30
- Target Recruit Count
- 165
- Registration Number
- NCT07172412
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China 300060, Tianjin, Tianjin Municipality, China
Personalized SBRT in Early-Stage Peripheral NSCLC
- Conditions
- Early-stage Peripheral Non-small Cell Lung Cancer
- First Posted Date
- 2025-09-11
- Last Posted Date
- 2025-09-11
- Target Recruit Count
- 251
- Registration Number
- NCT07167459
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin 300060, Tianjin, Tianjin Municipality, China
DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI
- Conditions
- Esophageal Cancer
- Interventions
- Procedure: SurgeryRadiation: RadiotherapyDrug: Chemotherapy
- First Posted Date
- 2025-09-09
- Last Posted Date
- 2025-09-17
- Target Recruit Count
- 120
- Registration Number
- NCT07162506
- Locations
- 🇨🇳
Tianjin Cancer Hospital, Tianjin, Tianjin Municipality, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 73
- Next
News
Chinese Drug Combination Outperforms Keytruda in Advanced Lung Cancer Trial
A Chinese-developed drug combination of Benmelstobart and Anlotinib demonstrated superior efficacy over pembrolizumab (Keytruda) in treating PD-L1-positive advanced non-small cell lung cancer patients.
Phase 2 Trial Shows Promise: Camrelizumab Plus Chemotherapy Effective for Advanced Nasopharyngeal Cancer in Non-Endemic Regions
A phase 2 trial demonstrates that combining camrelizumab immunotherapy with induction chemotherapy and chemoradiotherapy achieved an 84% 3-year disease-free survival rate in advanced nasopharyngeal cancer patients.
Pyrotinib Plus Metronomic Vinorelbine Shows Efficacy in HER2+ Advanced Breast Cancer Post-Trastuzumab
A phase 2 trial in China demonstrated that pyrotinib combined with metronomic vinorelbine is effective in HER2-positive advanced breast cancer patients after trastuzumab failure.